Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2008 1
2009 1
2010 2
2011 3
2014 1
2015 5
2016 2
2017 5
2018 5
2019 2
2020 3
2021 4
2022 4
2023 3
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review.
Kim PS, Fishman MA. Kim PS, et al. Curr Pain Headache Rep. 2020 Aug 26;24(10):64. doi: 10.1007/s11916-020-00898-0. Curr Pain Headache Rep. 2020. PMID: 32845365
PURPOSE OF REVIEW: The purpose of this review is to evaluate and explain our current understanding of the clinical use of low-dose naltrexone in the treatment of chronic pain. RECENT FINDINGS: Recent pre-clinical uses and clinical studies further elucidate th …
PURPOSE OF REVIEW: The purpose of this review is to evaluate and explain our current understanding of the clinical use of low-dose …
The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders.
Patten DK, Schultz BG, Berlau DJ. Patten DK, et al. Pharmacotherapy. 2018 Mar;38(3):382-389. doi: 10.1002/phar.2086. Epub 2018 Feb 23. Pharmacotherapy. 2018. PMID: 29377216 Review.
Due to the difficulty of treating these diseases and the great impact on quality of life, patients often seek off-label, complimentary, or alternative medicines to gain relief from symptoms. Low-dose naltrexone has been used off-label for treatment of pain an …
Due to the difficulty of treating these diseases and the great impact on quality of life, patients often seek off-label, complimentary, or a …
Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
Toljan K, Vrooman B. Toljan K, et al. Med Sci (Basel). 2018 Sep 21;6(4):82. doi: 10.3390/medsci6040082. Med Sci (Basel). 2018. PMID: 30248938 Free PMC article. Review.
Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial inflammatory response by modulating Toll-like receptor 4 signaling in addition to systemically upregulating endogenous opioid signaling by transient opio …
Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial inflammatory …
Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.
Li Z, You Y, Griffin N, Feng J, Shan F. Li Z, et al. Int Immunopharmacol. 2018 Aug;61:178-184. doi: 10.1016/j.intimp.2018.05.020. Epub 2018 Jun 7. Int Immunopharmacol. 2018. PMID: 29885638 Review.
Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. In recent years, there have been some novel and signi …
Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to …
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Younger J, Parkitny L, McLain D. Younger J, et al. Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15. Clin Rheumatol. 2014. PMID: 24526250 Free PMC article. Review.
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that LDN may operate as a novel anti-i …
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's …
Low-dose naltrexone reduced anxiety in persons with multiple sclerosis during the COVID-19 pandemic.
McLaughlin PJ, Odom LB, Arnett PA, Orehek S, Thomas GA, Zagon IS. McLaughlin PJ, et al. Int Immunopharmacol. 2022 Dec;113(Pt B):109438. doi: 10.1016/j.intimp.2022.109438. Epub 2022 Nov 9. Int Immunopharmacol. 2022. PMID: 36379151 Free PMC article.
Persons with multiple sclerosis (PwMS) have been considered at high risk for vaccination and/or acquisition of COVID-19 related to their reduced immune systems and daily regimen of immune suppressing therapy. Substantiated and unsubstantiated reports on these unknow …
Persons with multiple sclerosis (PwMS) have been considered at high risk for vaccination and/or acquisition of COVID-19 relate …
Evaluation of Low-Dose Naltrexone for Chronic Pain Management.
Spargo A, Gonser L, Faley B. Spargo A, et al. J Pain Palliat Care Pharmacother. 2025 Jun;39(2):319-322. doi: 10.1080/15360288.2025.2456279. Epub 2025 Feb 3. J Pain Palliat Care Pharmacother. 2025. PMID: 39901608
More recently, naltrexone has been used off-label at low doses of 4.5 mg daily for chronic pain due to fibromyalgia, neuropathy, complex regional pain syndrome, and multiple sclerosis. While several studies show the promise of low-dose …
More recently, naltrexone has been used off-label at low doses of 4.5 mg daily for chronic pain due to fibromyalgia, neuropath …
Low Dose Naltrexone in Dermatology.
Jaros J, Lio P. Jaros J, et al. J Drugs Dermatol. 2019 Mar 1;18(3):235-238. J Drugs Dermatol. 2019. PMID: 30909326
Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide range of conditions including Crohn's disease, fibromyalgia, major depressive disorder, cancer, chronic regional pain syndrome, Charcot-Mari …
Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide …
Low dose naltrexone therapy in multiple sclerosis.
Agrawal YP. Agrawal YP. Med Hypotheses. 2005;64(4):721-4. doi: 10.1016/j.mehy.2004.09.024. Med Hypotheses. 2005. PMID: 15694688
The use of low doses of naltrexone for the treatment of multiple sclerosis (MS) enjoys a worldwide following amongst MS patients. There is overwhelming anecdotal evidence, that in low doses naltrexone not only prevents relapses in MS but …
The use of low doses of naltrexone for the treatment of multiple sclerosis (MS) enjoys a worldwide following amo …
Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi-experimental study.
Raknes G, Småbrekke L. Raknes G, et al. PLoS One. 2017 Nov 3;12(11):e0187423. doi: 10.1371/journal.pone.0187423. eCollection 2017. PLoS One. 2017. PMID: 29099849 Free PMC article.
Low dose naltrexone (LDN) has become a popular off-label therapy for multiple sclerosis (MS). ...
Low dose naltrexone (LDN) has become a popular off-label therapy for multiple sclerosis (MS). ...
42 results